Halozyme has collaboration agreements for our proprietary ENHANZE^® drug delivery technology with Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion and argenx.

Learn more about our strategic partnerships.

We also seek nonclinical and clinical collaborations for our lead oncology asset, PEGPH20 (pegvorhyaluronidase alfa), to study its pan-tumor potential. PEGPH20 is currently under investigation for the treatment of several cancers and has the potential to be used in combination with different types of cancer therapies.

Visit the Investigators section of our website to learn more about these opportunities.

For more information on partnering with Halozyme, please contact a member of the Business Development Team.